T. Rowe Price Associates
XGN icon

T. Rowe Price Associates’s Exagen XGN Stock Holding History

T. Rowe Price Associates’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-477,630
Closed -$12.1M – 2567
2019
Q4 		$12.1M Sell
477,630
-22,370
-4% -$398K ﹤0.01% 1281
2019
Q3 		$7.75M Buy
+500,000
New +$8.07M ﹤0.01% 1323

Other funds holding XGN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

T. Rowe Price Associates's XGN Position: Q1 2020 in Review

T. Rowe Price Associates sold out of Exagen (XGN) in Q1 2020, closing a stake of 477,630 shares — an estimated $12.1M sold.

T. Rowe Price Associates first reported a position in XGN in Q3 2019 and held it in 2 quarters. The position peaked at $12.1M in Q4 2019. 32 funds tracked by Wall St. Rank hold XGN as of Q1 2020.

  • T. Rowe Price Associates reported no remaining Exagen position as of Q1 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 477,630 Exagen shares in Q1 2020, an estimated $12.1M.
  • T. Rowe Price Associates first reported a position in Exagen in Q3 2019 and held it in 2 quarters.
  • T. Rowe Price Associates's Exagen position peaked at $12.1M in Q4 2019.
  • 32 funds tracked by Wall St. Rank held Exagen as of Q1 2020.

Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.